Neuropore introduces a 2nd drug into the clinic. Has an eye for Parkinson's disease and ALS.
Neuropore Therapies announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable, blood-brain barrier penetrating small molecule. Its mode of action is attenuation of neuroinflammation and reduction of neurotoxic misfolded proteins in the central nervous system, key features of neurodegenerative diseases including Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS).
Full press release: https://www.businesswire.com/news/home/20190508005227/en/Neuropore-Initiates-Phase-1-Clinical-Trial-Healthy
Sign in with